Artificial Intelligence1 min read

Venture firm Flagship bets £100 million to build AI-driven drug companies in Britain

By · Published by Everything Blog

In short

The effort establishes a startup creation hub near the Francis Crick Institute following three years of groundwork alongside British regulators and universities. Flagship intends to leverage its initial capital to draw at least £500 million in external partner financing rather than simply buying equity in pre-existing businesses. To staff the new enterprise builder, the firm plans to recruit around 50 local operators and scientist-entrepreneurs.

Key points

  • The presence of comprehensive patient records across the National Health Service served a…: The presence of comprehensive patient records across the National Health Service served as the primary motivation for the overseas expansion.
  • Flagship expects its initial £100 million commitment to ultimately mobilize £500 million…: Flagship expects its initial £100 million commitment to ultimately mobilize £500 million or more in co-investment from institutional partners.
  • Chief executive Noubar Afeyan noted that the deployment of artificial intelligence in pha…: Chief executive Noubar Afeyan noted that the deployment of artificial intelligence in pharmaceutical development remains in its early stages.

Sources checked by our analysis pipeline: 1

LONDON, Nov 16 : Flagship Pioneering is opening its first lab for creating companies outside the United States, putting £100 million ($131.94 million) behind a new UK-based effort to fund and build AI-driven biotech companies, the venture firm said on Monday.

The move is a first for a firm that has created more than 130 companies, including Moderna, and operated only from the United States for more than 25 years.

Flagship's move comes after three years of groundwork in Britain. The company opened its London office in 2023 near the Francis Crick Institute in King’s Cross and its local team has since built partnerships with academia, government and regulatory groups.

"We concluded that this might well be the right next step in our evolution," Noubar Afeyan, founder and CEO of the venture firm, told Reuters in an interview. The Flagship Origination lab will be anchored at the firm's London office.

Afeyan said that the firm will not buy into existing companies, and instead plans to "cast a wide net" for partnerships with universities, corporations and funders.

It hopes its £100…

Artificial Intelligence